Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.55 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.51 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28846634 | 0.82 | TSHR (0.59) | TSHRALDH1A1NOTUMMRGPRX4PBRM1 | |
| SCHEMBL7979358 | 0.82 | AKR1C3 (0.47) | TSHRALDH1A1NOTUMMRGPRX4GAA | |
| SCHEMBL400760 | 0.79 | NR4A2 (0.48) | TSHRALDH1A1NOTUMMEN1KMT2A | |
| SCHEMBL28363838 | 0.79 | CYP1A2 (0.52) | TSHRALDH1A1NOTUMMRGPRX4GAA | |
| SCHEMBL4851536 | 0.78 | ALDH1A1 (0.44) | TSHRALDH1A1NOTUMMRGPRX4GAA | |
| SCHEMBL27752895 | 0.78 | ALDH1A1 (0.54) | TSHRALDH1A1NOTUMMRGPRX4ALOX15 | |
| SCHEMBL16960857 | 0.78 | KDM4E (0.44) | TSHRALDH1A1NOTUMMRGPRX4GAA | |
| SCHEMBL30961765 | 0.77 | ALB (0.55) | TSHRALDH1A1NOTUMMRGPRX4ALOX15 | |
| SCHEMBL1352723 | 0.77 | KDM4E (0.55) | TSHRALDH1A1NOTUMMRGPRX4ALOX15 | |
| SCHEMBL28331532 | 0.77 | ALB (0.55) | TSHRALDH1A1NOTUMMRGPRX4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106536515-B | Compound as immunomodulator | 百时美施贵宝公司 | 2019-08-16 | — | — | CN | disclosed |
| EP-3131876-B1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-11-07 | — | — | EP | disclosed |
| US-9850225-B2 | Compounds useful as immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850225-B2 | Compounds useful as immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-26 | — | — | US | disclosed |
| CN-106536515-A | Compounds useful as immunomodulators | 百时美施贵宝公司 | 2017-03-22 | — | — | CN | disclosed |
| EP-3131876-A2 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-2424869-B1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LTD (GB) | 2016-06-22 | — | — | EP | disclosed |
| EP-2424869-B1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LTD (GB) | 2016-06-22 | — | — | EP | disclosed |
| WO-2015160641-A2 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-22 | — | — | WO | disclosed |
| WO-2015160641-A2 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-22 | — | — | WO | disclosed |
| US-8101621-B2 | Aminopyridine derivatives having aurora a selective inhibitory action | MSD K.K. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-8101621-B2 | Aminopyridine derivatives having aurora a selective inhibitory action | MSD K.K. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-8101621-B2 | Aminopyridine derivatives having aurora a selective inhibitory action | MSD K.K. (JP) | 2012-01-24 | — | — | US | disclosed |
| WO-2010125102-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010125102-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
| US-20090192174-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090192174-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090192174-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| EP-2017279-A1 | NOVEL AMINOPYRIDINE DERIVATIVE HAVING AURORA-A-SELECTIVE INHIBITORY ACTIVITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-21 | — | — | EP | disclosed |
| EP-2017279-A1 | NOVEL AMINOPYRIDINE DERIVATIVE HAVING AURORA-A-SELECTIVE INHIBITORY ACTIVITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192174-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | RB1, AURKA, AURKC | TSHR 2388/4885ALDH1A1 1967/4885NOTUM 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.